Generic competition · all medicines · read 12 November 2026
Is there a generic of Minocycline Hydrochloride, and who makes it?
Minocycline Hydrochloride appears in 8 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 12 generic makers listed as marketed across them. 4 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 0.2 and 20.7 years after the first brand approval. This is the Orange Book's listing, not a forecast.
Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.
- Minocycline Hydrochloride appears in 8 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 12 generic makers listed as marketed across them.
- 4 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
- Where both are dated, the first generic approval came between 0.2 and 20.7 years after the first brand approval.
- Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.
Tablet, Extended Release, Oral
Four or more generic makers listed
Every brand product here is listed as discontinued. 4 generic makers with 23 generic products listed as marketed; the first generic approval is dated 3 February 2009.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Sandoz Inc | 13 August 2009 | 3 |
| Lupin Ltd | 30 November 2011 | 4 |
| Aurobindo Pharma Ltd | 19 November 2012 | 8 |
| Alkem Laboratories Ltd | 28 September 2016 | 8 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Capsule, Oral
Four or more generic makers listed
Brand listed as marketed: Minocin. 6 generic makers with 15 generic products listed as marketed; the first generic approval is dated 31 July 1990.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Watson Laboratories Inc | 30 December 1991 | 2 |
| Watson Laboratories Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc | 30 December 1991 | 1 |
| Zydus Worldwide Dmcc | 2 March 1992 | 3 |
| Impax Laboratories Inc | 23 March 1999 | 3 |
| Torrent Pharmaceuticals Ltd | 30 November 2000 | 3 |
| Aurobindo Pharma Ltd | 11 March 2008 | 3 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Tablet, Oral
Four or more generic makers listed
Every brand product here is listed as discontinued. 5 generic makers with 15 generic products listed as marketed; the first generic approval is dated 16 April 2003.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Strides Pharma International Ag | 16 April 2003 | 3 |
| Torrent Pharmaceuticals Ltd | 6 January 2004 | 3 |
| Chartwell Rx Sciences Llc | 26 December 2007 | 3 |
| Aurobindo Pharma Ltd | 1 May 2020 | 3 |
| Regcon Holdings Llc | 27 May 2022 | 3 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Capsule, Extended Release, Oral
Brand listed, no generic listed as marketed
Brand listed as marketed: Emrosi. No generic is listed as marketed.
Patents and exclusivities still listed
- 1 November 2027Exclusivity NP Emrosi
- 7 January 2039Patent 11364212
- 7 January 2039Patent 11191740
- 7 January 2039Patent 10905664
- 7 January 2039Patent 12594252
Aerosol, Foam, Topical
Brand listed, no generic listed as marketed
Brand listed as marketed: Amzeeq and Zilxi. No generic is listed as marketed.
Patents and exclusivities still listed
- 1 October 2030Patent 10137200
- 1 October 2030Patent 8865139 drug product
- 1 October 2030Patent 9675700 drug product
- 1 October 2030Patent 8992896 drug product
- 1 October 2030Patent 10086080
- 1 October 2030Patent 10213512 drug product
- 1 October 2030Patent 10517882
- 1 October 2030Patent 10821187
8 more patents are listed.
Injectable, Injection
Brand listed, no generic listed as marketed
Brand listed as marketed: Minocin. No generic is listed as marketed (1 generic product listed as discontinued).
Patents and exclusivities still listed
- 12 May 2031Patent 9084802
- 12 May 2031Patent 9278105
- 12 May 2031Patent 12161656 drug product
- 16 October 2032Patent 11944634 drug product
Powder, Extended Release, Dental
Brand listed, no generic listed as marketed
Brand listed as marketed: Arestin. No generic is listed as marketed.
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Suspension, Oral
Nothing listed as marketed
Every brand product here is listed as discontinued. No generic is listed as marketed.
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.
Where can you go from this result?
Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.